On the afternoon of February 14, 2023, Chairman Professor Shi Yuanyuan, Chief Scientist Professor Wang Jianxun, Deputy General Manager Tang Xiaomeng, and Assistant to the Chairman Wei Zheng visited the He Yuan Bio Beijing Operations Center for exchange and discussion. The He Yuan Bio team, including Founder and CEO Lv Lulu, Chief Scientist Zhou Li, Chief Technology Officer Wang Yongzeng, SVP of Operations Zhao Linhai, VP of Business Development Zhu Yi, Strategy Director Deng Yiping, and CEO Assistant Liu Shaozhou, extended a warm welcome and held symposium discussions. As a leading domestic cell therapy drug development enterprise, He Yuan Bio has obtained three IND clinical approvals in China, with its CD19-targeted CAR-T drug CNCT19 cell injection expected to receive approval soon, potentially becoming the first independently developed CD19-targeted CAR-T product to enter the market.

During the symposium, Chairman Shi Yuanyuan first introduced the founding vision, development history, core team, research advantages, and strategic positioning of Cell Valley. He Yuan Bio CEO Lv Lulu provided a detailed introduction to the company's development. The two teams engaged in discussions on the use, production volume, concentration methods, and the dominant domestic market share of lentiviral vectors. Chairman Shi and Chief Scientist Wang Jianxun analyzed the current global distribution of different viral vector types in R&D pipelines and the development status of the domestic viral vector industry. They also highlighted the necessity of establishing retroviral vector production lines from multiple perspectives, including safety, viral vector titers, industrial cost advantages, and industrial layout.

The He Yuan Bio team expressed strong agreement with Shenzhen Cell Valley's in-depth analysis and stated that, although their existing lentiviral vector product line is mature, they are open to collaborating with Shenzhen Cell Valley in new pipeline R&D, new product line establishment, and the construction of R&D and production facilities in South China. They expressed a desire to jointly develop cell-based drugs based on retroviral vector technology and accelerate the high-speed development of the cell therapy industry.

Both teams committed to promptly implementing the spirit of the meeting, initiating new pipeline R&D as soon as possible, and laying a solid foundation for comprehensive strategic cooperation.

Founded in June 2018, He Yuan Bio is a next-generation biopharmaceutical enterprise driven by innovative cell and gene technologies. Through deep collaboration with national top-tier research institutions and clinical research centers, the company has established an international new drug R&D innovation system centered on its CAR technology platform, iPSC technology platform, and gene editing technology platform. Focusing on the R&D and commercialization of innovative immunocellular therapies, He Yuan Bio is committed to building a globally leading platform for cell therapy drug R&D, clinical translation, and commercialization.